M
Michael A. Matthay
Researcher at University of California, San Francisco
Publications - 1063
Citations - 110857
Michael A. Matthay is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Lung injury & Lung. The author has an hindex of 151, co-authored 998 publications receiving 98687 citations. Previous affiliations of Michael A. Matthay include University of California & Cardiovascular Institute of the South.
Papers
More filters
Journal ArticleDOI
Plasma metabolic profiling implicates dysregulated lipid metabolism and glycolytic shift in hyperinflammatory ARDS.
N. Alipanah-Lechner,L. Neyton,Eran Mick,Andrew Willmore,Aleksandra Leligdowicz,Kévin Contrepois,Alejandra Jáuregui,Hanjing Zhuo,Carolyn M. Hendrickson,Antonio Gomez,Pratik Sinha,Kirsten N. Kangelaris,Kathleen D. Liu,Michael A. Matthay,Angela J. Rogers,Carolyn S. Calfee +15 more
TL;DR: Using latent class analysis (LCA) of clinical and protein biomarkers, researchers have identified two phenotypes of the acute respiratory distress syndrome (ARDS) with divergent clinical trajectories and treatment responses as discussed by the authors .
Journal ArticleDOI
New Insights into Clinical and Mechanistic Heterogeneity of the Acute Respiratory Distress Syndrome: Summary of the Aspen Lung Conference 2021.
Thomas R. Martin,Rachel L. Zemans,Lorraine B. Ware,E. E. Schmidt,David W. Rice,Lisa Bastarache,Carolyn S. Calfee,Tushar J. Desai,Susanne Herold,Catherine L. Hough,Mark R. Looney,Michael A. Matthay,Nuala J. Meyer,Samir M. Parikh,Troy Stevens,B. Taylor Thompson +15 more
TL;DR: This report summarizes the proceedings of the 2021 Aspen Lung Conference, which was organized to review key issues related to understanding clinical and molecular heterogeneity in ARDS, to explore multicellular and multisystem mechanisms responsible for heterogeneity and to review how best to account for clinical and Molecular heterogeneity in clinical trial design and assessment of outcomes.
Journal ArticleDOI
Report of the first seven agents in the I-SPY COVID trial: a phase 2, open label, adaptive platform randomised controlled trial
D. Clark Files,Neil R. Aggarwal,Timothy E Albertson,Sara C. Auld,Jeremy R. Beitler,Paul A Berger,Ellen L. Burnham,Carolyn S. Calfee,Nathan K. Cobb,Alessio Crippa,Andrea Discacciati,Martin Eklund,Laura J. Esserman,E L Friedman,Sheetal Gandotra,Kashif Khan,Jonathan L. Koff,Santhi Iyer Kumar,Kathleen D. Liu,Thomas R. Martin,Michael A. Matthay,Nuala J. Meyer,Timothy Obermiller,Philip Robinson,Derek Russell,Karl Thomas,Se Fum Wong,Richard G. Wunderink,Mark M. Wurfel,A. F. Yen,Fady Youssef,Anita Darmanian,Amy L. Dzierba,Ivan Garcia,Katarzyna Gosek,Purnema Madahar,Aaron M. Mittel,Justin Muir,Amanda Rosen,John Schicchi,Alexis Serra,Romina Wahab,Kevin W Gibbs,Leigha Landreth,Mary Elizabeth Larose,Lisa Fujie Parks,Adina S. Wynn,Caroline A. G. Ittner,Nilman S. Mangalmurti,John P. Reilly,Donna Harris,Abhishek R. Methukupally,Siddharth Manilal Patel,LM Boerger,John A. Kazianis,Carrie Higgins,Jeffrey McKeehan,Brian M. Daniel,S.Z. Fields,James Hurst-Hopf,Alejandra Jáuregui,Lamorna Brown Swigart,Daniel D. Blevins,Catherine Nguyen,Alexis Suarez,Maged Tanios,Farjad Sarafian,Usman Shah,Max Adelman,Christina Creel-Bulos,Joshua F. Detelich,Gavin Harris,Katherine Lyn Nugent,Christine Spainhour,Philip Yang,Angela Franciska Haczku,Erin Hardy,Richart W Harper,Brian E. Morrissey,Christian Sandrock,G. R. Scott Budinger,Helen K. Donnelly,Benjamin D. Singer,Ari Moskowitz,Melissa Coleman,Joseph E. Levitt,R. Lu,Paul Henderson,Adam Asare,Imogene Dunn,Alejandro Botello Barragan +90 more
TL;DR: In this paper , the adaptive platform design was used to rapidly evaluate investigational agents, hospitalised patients with severe COVID-19 requiring ≥6 L/min oxygen were randomised to either a backbone regimen of dexamethasone and remdesivir alone (controls) or backbone plus one open-label investigational agent.
Journal ArticleDOI